23andMe CEO on Trading Debut, GSK Deal, Branson SPAC

The video discusses 23andMe's decision to go public, emphasizing the company's maturity and readiness. It highlights the focus on expanding the therapeutic side of the business, including collaborations with GSK. The role of DNA testing in personalized healthcare and privacy concerns are addressed. The choice of a SPAC over a traditional IPO is explained, with Richard Branson as a key partner. Future plans include enhancing personalized healthcare and conducting COVID-related research.

How does 23andMe engage individuals in their health and research?

What is the vision for 23andMe in the next five years?

What research is 23andMe planning to conduct regarding long COVID?